Live feed02:00:00·208dPRReleasevia QuantisnowPureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPFByQuantisnow·Wall Street's wire, on your screen.PRTC· PureTech Health plcHealth Care
